| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab179385-100μg |
100μg |
现货  |
| |
| Ab179385-1mg |
1mg |
现货 |
| |
| Ab179385-5mg |
5mg |
现货 |
| |
| Ab179385-10mg |
10mg |
期货 |
|
| 产品名称 | Geptanolimab (anti-PDCD1) |
|---|---|
| 别名 | 杰洛利单抗 | 庚妥尼单抗（抗 PDCD1） |
| 英文别名 | CD279 antibody | CD279 antigen antibody | hPD 1 antibody | hPD l antibody | hPD-1 antibody | hSLE1 antibody | PD 1 antibody | PD-1 antibody | PD1 antibody | PDCD 1 antibody | PDCD1 antibody | PDCD1_HUMAN antibody | Programmed cell death 1 antibody | Progr |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | PDCD1 |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG4SP |
| 轻链亚型 | kappa |
| SDS-PAGE | 27.9 kDa (Light Chain) & 50.2kDa (Heavy Chain), under reducing conditions; 186.0kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0. |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 2348469-43-0 |
| 分子类型 | 抗体 |
Geptanolimab (anti-PDCD1) (Ab179385) - Flow Cytometry
Flow Cytometry analysis of 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated MOLT-4 cells (24h) labelling PDCD1 (red) with Geptanolimab (anti-PDCD1) (Ab179385). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Geptanolimab (anti-PDCD1) (Ab179385) - SEC
The purity of Geptanolimab (anti-PDCD1) (Ab179385) is more than 95% verified by HPLC.
| 活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ24F1114063 |
分析证书 | 24-11-20 | Ab179385 |
| ZJ24F1114062 |
分析证书 | 24-11-20 | Ab179385 |
| ZJ24F1114061 |
分析证书 | 24-11-20 | Ab179385 |
| ZJ24F0404203 |
分析证书 | 24-04-08 | Ab179385 |
| ZJ24F0404204 |
分析证书 | 24-04-08 | Ab179385 |
| ZJ24F0404205 |
分析证书 | 24-04-08 | Ab179385 |
¥579.90
¥431.92
¥455.92
¥579.90
¥579.90
¥535.92
¥669.90
¥199.90
¥669.90
¥449.90
¥299.90
¥669.90
¥169.90
¥669.90
¥899.90
¥669.90
¥479.92
¥499.90
¥319.92
¥579.90
| 1. Kline J, Gajewski TF. (2010) Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.. Curr Opin Investig Drugs, 11 (12): (1354-9). [PMID:21154117] [10.1021/op500134e] |
| 2. Hall RD, Gray JE, Chiappori AA. (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.. Cancer Control, 20 (1): (22-31). [PMID:23302904] [10.1021/op500134e] |
| 3. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al.. (2017) Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.. Mol Cancer Ther, 16 (5): (861-870). [PMID:28265006] [10.1021/op500134e] |
| 4. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. (2015) Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.. Structure, 23 (12): (2341-2348). [PMID:26602187] [10.1021/op500134e] |
| 5. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips. (1997-10-23) The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors.. Gene, 197 ((1-2)): (177-187). [PMID:9332365] |
| 6. Cheng B, Ren Y, Niu X, Wang W, Wang S, Tu Y, Liu S, Wang J, Yang D, Liao G, Chen J.. (2020) Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.. J Med Chem, 63 (15): (8338-8358). [PMID:32667799] [10.1021/acs.jmedchem.0c00574] |
| 7. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T.. (1994) Structure and chromosomal localization of the human PD-1 gene (PDCD1).. Genomics, [PMID:7851902] |
| 8. Prokunina, Ludmila L and 23 more authors.. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.. Nature genetics, [PMID:12402038] |
| 9. Topalian, Suzanne L SL and 29 more authors.. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.. The New England journal of medicine, (28): [PMID:22658127] |
| 10. Robert, Caroline C and 27 more authors.. (2015) Nivolumab in previously untreated melanoma without BRAF mutation.. The New England journal of medicine, (22): [PMID:25399552] |
| 11. McDermott, J J and Jimeno, A A.. (2015) Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.. Drugs of today (Barcelona, Spain : 1998), [PMID:25685857] |
| 12. Na, Zhenkun and 6 more authors.. (2017) Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.. Cell research, [PMID:27325296] |
| 13. Pascolutti, Roberta R and 6 more authors.. (2016) Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.. Structure (London, England : 1993), (4): [PMID:27618663] |
| 14. Horita, Shoichiro S and 5 more authors.. (2016) High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.. Scientific reports, (13): [PMID:27734966] |
| 15. Tan, Shuguang S and 15 more authors.. (2017) An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.. Nature communications, (6): [PMID:28165004] |
| 16. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ.. (2018) PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.. Gene, (5): [PMID:28951311] |
首页
400-620-6333
